HIV and dyslipidemia
Conditions
Interventions
Switch from Efavirenz 600mg to rilpivirine 25mg oral once daily,
duration 24 weeks
Active Comparator Drug
Rilpivirine
Sponsors
Infectious disease association of Thailand
University Hospital,
Srinagarind
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Inclusion Criteria: -HIV-1 infected adults, who were receiving antiretroviral therapy including efavirenz for at least 6 months -plasma HIV RNA130 mg/dL in the presence of at least one of the 3 following coronary heart disease (CHD) risk factors: age>45 among males or age>55 among females, hypertension, current smoking, family history of CHD,DM -Low-Density Lipoprotein cholesterol (LDL-c)>160 mg/dL regardless of CHD risk factors. -Diagnosed dyslipidemia and current treatment with lipid lowering agent
Exclusion criteria
Exclusion criteria: -Receive ongoing therapy with proton pump inhibitor, rifamycin, carbamazepine, oxcarbamazepine, phenobarbital, phenytoin,systemic steroid and St John’s wort -Asparate aminotransferase (AST) or alanine aminotransferase (ALT) >3N -Pregnancy -Severe depression
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Decrease in LDL cholesterol between baseline and week 24 at 6 months after end of the intervention Measure LDL cholesterol level | — |
Secondary
| Measure | Time frame |
|---|---|
| Viral suppression and Depression at 6 months after end of the intervention Thai Depresssive Inventory score | — |
Countries
Thailand
Contacts
Public ContactPornpimol Laovachirasuwan
Srinagarind hospital
Outcome results
None listed